ADVOCACY

brussels 4056171 1920


EAACI seeks to tackle the burden of allergy in Europe with evidence-based recommendations and by joining forces with relevant European actors in the field.

To find out  about our initiatives at the EU level, upcoming events and campaigns :

readmore


European Parliament Interest Group on Allergy and Asthma

allasth
The European Parliament Interest Group on Allergy and Asthma was launched on 25 March 2015 as a result of a long-standing collaboration between the European Academy of Allergy and Clinical Immunology (EAACI), the European Federation of Allergy and Airways Diseases Patients’ Associations (EFA), and a group of forward-thinking Members of the European Parliament (MEPs), who are committed to fight against allergy and asthma in Europe. The European Parliament Interest Group on Allergy and Asthma is a policy forum to share expertise and align interests engaging with EU policy-makers and stakeholders on allergy and asthma health.
More than 150 million EU citizens live with chronic allergic diseases. If you want to know more about how to treat these diseases and to support better policies for people living with allergies and asthma through your parliamentary work and beyond, we invite you to join our group.

Read more about the Interest Group Activities here.

EAACI maintains strong collaborations with:

EFA logo OFFICIAL European Federation of Allergy and Airways Diseases Patients’ Associations (EFA) to advocate better patient care  
ECDA logo September 2019 002
European Chronic Disease Alliance (ECDA) to raise awareness among policy makers about the surge in chronic diseases

logo fullname HD 1 Alliance for Biomedical Research in Europe (BioMed Alliance) to promote excellence and innovation in European biomedical research
EMA European Medicines Agency (EMA) to support safe and effective quality interventions for allergic diseases and asthma



-



The European Strategic Forum on Allergic Diseases

The European Academy of Allergy and Clinical Immunology (EAACI) organized the first European Strategic Forum on Allergic Diseases and Asthma. The main aim was to bring together all relevant stakeholders and decision‐makers in the field of allergy, asthma and clinical Immunology around an open debate on contemporary challenges and potential solutions for the next decade. The Strategic Forum was an upscaling of the EAACI White Paper aiming to integrate the Academy's output with the perspective offered by EAACI's partners. This collaboration is fundamental for adapting and integrating allergy and asthma care into the context of real‐world problems. The Strategic Forum on Allergic Diseases brought together all partners who have the drive and the influence to make positive change: national and international societies, patients’ organizations, regulatory bodies and industry representatives. An open debate with a special focus on drug development and biomedical engineering, big data and information technology and allergic diseases and asthma in the context of environmental health concluded that connecting science with the transformation of care and a joint agreement between all partners on priorities and needs are essential to ensure a better management of allergic diseases and asthma in the advent of precision medicine together with global access to innovative and affordable diagnostics and therapeutics.


Read the full manuscript here.

Last updated 06 November 2019
Privacy Policy - disclaimer

EAACI recently updated its privacy policy and would like to highlight some key bits of information with you.

  • EAACI does not distribute, share or sell your information;
  • For technical and administrative purposes some information that can be used to identify you may be forwarded to third parties. For example, to process your registration for the EAACI Annual Congress and other EAACI events;
  • The Academy may also send you e-mail messages with news from the society. If you would like to no longer receive them, you can unsubscribe at any time by using the unsubscribe link in any of our communications;
  • You may also update your preferences or your profile information at any time by contacting us.

To continue please confirm that you agree with our updated privacy policy.

Thank you!

You have successfully agreed the new privacy policy – disclaimer.

Thank you!

You disagreed with the new privacy policy – disclaimer and your feedback will be reviewed as soon as possible.

Agree & Continue
Disagree
Send feedback
Cancel